Nabriva gets first approval in novel antibiotic class

Nabriva gets first approval in novel antibiotic class

Source: 
BioCentury
snippet: 

Nabriva plans to launch its first approved antibiotic, Xenleta lefamulin, in mid-September to treat community-acquired bacterial pneumonia, and the company has taken steps to facilitate Xenleta's adoption through negotiations with healthcare providers, payers and pharmacies.